<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypomethylating drugs are useful and have been approved for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011010'>Chronic</z:hpo> Myelomonocytic <z:hpo ids='HP_0001909'>Leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, phase 2 and 3 studies that assessed these agents in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, have included only a small number of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, and there are just a few specific reports on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:chebi fb="0" ids="2038">Azacitidine</z:chebi> is actually authorised for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients with 10-29% marrow blasts without <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo>, who are not eligible for haematopoietic stem cell transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>This hypomethylating agent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is known for causing transient cytopenias, most often occurring during the first 2 cycles </plain></SENT>
<SENT sid="4" pm="."><plain>Here we report a case of an atypical delayed and prolonged hematologic toxicity during <z:chebi fb="0" ids="2038">Azacitidine</z:chebi> treatment in a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patient; furthermore we also reviewed the literature regarding the efficacy of the drug and the management of hematologic adverse effects, in term of dose adjustments or alternative schedule of administration, in specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> setting </plain></SENT>
</text></document>